Clinical utility of varenicline for smokers with medical and psychiatric comorbidity.

Jon Owen Ebbert, Kirk D. Wyatt, Ali Zirakzadeh, Michael V. Burke, James Taylor Hays

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

Original languageEnglish (US)
Pages (from-to)421-430
Number of pages10
JournalInternational journal of chronic obstructive pulmonary disease
Volume4
StatePublished - 2009

Fingerprint

Chronic Obstructive Pulmonary Disease
Psychiatry
Comorbidity
Smoking Cessation
Tobacco Products
Hope
Smoke
Acetylcholine
Tobacco
Cardiovascular Diseases
Smoking
Drug Therapy
Lung
Mortality
Varenicline
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Clinical utility of varenicline for smokers with medical and psychiatric comorbidity. / Ebbert, Jon Owen; Wyatt, Kirk D.; Zirakzadeh, Ali; Burke, Michael V.; Hays, James Taylor.

In: International journal of chronic obstructive pulmonary disease, Vol. 4, 2009, p. 421-430.

Research output: Contribution to journalArticle

@article{f5cb21b07c1f47f1a5e23c4c97ee8d30,
title = "Clinical utility of varenicline for smokers with medical and psychiatric comorbidity.",
abstract = "Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5{\%} of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.",
author = "Ebbert, {Jon Owen} and Wyatt, {Kirk D.} and Ali Zirakzadeh and Burke, {Michael V.} and Hays, {James Taylor}",
year = "2009",
language = "English (US)",
volume = "4",
pages = "421--430",
journal = "International Journal of COPD",
issn = "1176-9106",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Clinical utility of varenicline for smokers with medical and psychiatric comorbidity.

AU - Ebbert, Jon Owen

AU - Wyatt, Kirk D.

AU - Zirakzadeh, Ali

AU - Burke, Michael V.

AU - Hays, James Taylor

PY - 2009

Y1 - 2009

N2 - Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

AB - Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

UR - http://www.scopus.com/inward/record.url?scp=77949510361&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949510361&partnerID=8YFLogxK

M3 - Article

VL - 4

SP - 421

EP - 430

JO - International Journal of COPD

JF - International Journal of COPD

SN - 1176-9106

ER -